Summary
Active ingredients from medicines can get into the environment through a variety of routes, and once there they can prove harmful to wildlife and ecosystems. In the EU, new medicines are required to undergo an environmental risk assessment (ERA). However, so far just a handful of the 1900 or so active pharmaceutical ingredients (APIs) in use have been assessed.
The aim of PREMIER is to deliver a framework for assessing and characterising the environmental risks of APIs. This framework could be used to prioritise and screen older (‘legacy’) APIs that have never been through an ERA. It could also be used to pick up potential environmental risks in new APIs that are still under development.
PREMIER also hopes its work will contribute to greener drug design in general, and help to make environmental data on APIs more visible and accessible to all stakeholders.
Achievements & News
March 2022
Scientists from IMI’s iPiE and PREMIER projects used ePiE to predict levels of ibuprofen in four major European river basins.
Participants
Show participants on mapEFPIA companies
- Astrazeneca AB, Södertälje, Sweden
- Bayer Aktiengesellschaft, Leverkusen, Germany
- Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
- Institut De Recherches Internationales Servier Iris, Suresnes, France
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
- Novartis Pharma AG, Basel, Switzerland
- Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
- Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewaesserschutz, Duebendorf, Switzerland
- Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V., München, Germany
- Goeteborgs Universitet, Gothenburg, Sweden
- Istituto Di Ricerche Farmacologiche Mario Negri, Milano, Italy
- Leuphana Universitat Luneburg, Luneburg, Germany
- Rijksinstituut Voor Volksgezondheid En Milieu, Bilthoven, Netherlands
- Stichting Radboud Universiteit, Nijmegen, Netherlands
- The European Medicines Agency, Canary Wharf, London, United Kingdom
- The University Of Exeter, Exeter, United Kingdom
- University Of York, York, United Kingdom
- University of Helsinki, University of Helsinki, Helsinki, Finland
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- ECOLOGIC INSTITUT gemeinnützige GmbH, Berlin, Germany
- Ect Oekotoxikologie GMBH, Flörsheim a.M., Germany
- Simomics Limited, York, United Kingdom
- Teamit Research SL, Barcelona, Spain
| Participants | |
|---|---|
| Name | EU funding in € |
| ECOLOGIC INSTITUT gemeinnützige GmbH | 172 586 |
| Ect Oekotoxikologie GMBH | 363 498 |
| Eidgenoessische Anstalt Fuer Wasserversorgung Abwasserreinigung Und Gewaesserschutz | 296 498 |
| Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | 254 244 |
| Goeteborgs Universitet | 226 250 |
| Istituto Di Ricerche Farmacologiche Mario Negri | 224 375 |
| Leuphana Universitat Luneburg | 199 500 |
| Rijksinstituut Voor Volksgezondheid En Milieu | 288 385 |
| Simomics Limited | 413 728 |
| Stichting Radboud Universiteit | 725 309 |
| Teamit Research SL | 326 875 |
| The European Medicines Agency | 47 000 |
| The University Of Exeter | 314 776 |
| University of Helsinki | 312 141 |
| University Of York | 384 837 |
| Total Cost | 4 550 002 |
Ad Ragas
Stichting Radboud Universiteit